The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically ...

On International Men's Day, the Clinical Trials Arena team investigates three therapies being investigated in prostate cancer ...

Furthermore, docetaxel (the drug of choice for the ... BM: Brain metastasis; CRPC: Castration-resistant prostate cancer; CT: Computed tomography; NA: Not assessed; NMR: Nuclear magnetic resonance ...

ONCOLife proudly presents an exclusive interview with Dr. Iris Kuss, VP and Global Development Lead Oncology at Bayer. In ...

prostate cancer and non-small cell lung cancer either alone or with other medications. It belongs to taxane group. It stops the growth and spread of cancer cells. When should Docetaxel not be taken?

Bayer BAYRY announced that the FDA has accepted its supplemental new drug application (sNDA) for Nubeqa (darolutamide). The ...

The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate ...

The US regulator has approved Nubeqa (darolutamide) in combination with docetaxel chemotherapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), adding to its earlier ...